The California Institute for Regenerative Medicine, California’s voter-established stem cell agency, is thinking about its future. The institute recently issued a strategic plan for the next five years that it says represents a “radical overhaul of the way the institute conducts business” and emphasizes “coordination, speed, partnerships, and patients.” We spoke to Randy Mills, president of the California Institute for Regenerative Medicine, about the strategic plan, the ambitious goal it has set for the next five years, and whether CIRM will have a life beyond the $3 billion voters approved for its funding.
Fler avsnitt av The Bio Report
Visa alla avsnitt av The Bio ReportThe Bio Report med Levine Media Group finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
